Please login to the form below

dermatitis

This page shows the latest dermatitis news and features for those working in and with pharma, biotech and healthcare.

China updates drug reimbursement list, agrees price cuts

The key drugs which have been added to the list include AbbVie’s blockbuster drug Humira (adalimumab), Novartis’ dermatitis drug Xolair (omalizumab) and Roche’s HER2 breast cancer treatment Perjeta (petuzumab).

Latest news

Sanofi said to be looking at options for $30bn consumer health unit

Sanofi has had a difficult few years following the loss of patent protection for its former diabetes cash cow Lantus (insulin glargine), with some pipeline successes – notably atopic dermatitis and asthma
Dupixent gains can’t keep Sanofi on a growth track

First launched for atopic dermatitis in 2016, label extensions to include adolescent AD patients as well as asthma and chronic rhinosinusitis with nasal polyps helped sales of Regeneron-partnered Dupixent (dupilumab)
Sanofi/Regeneron wins another EU approval for Dupixent

It is also approved in patients 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. ... Aside from the EU, Dupixent has been approved for use in specific patients with moderate-to-severe atopic dermatitis
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

atopic dermatitis – also known as eczema – suggested there was little chance of a positive outcome. ... Atopic dermatitis is the most common form of eczema and can affect males and females of all ages, but often starts in childhood.
Dupixent drives Sanofi again, but other new drugs are lagging

Continued growth in atopic dermatitis, helped by approval in younger patients, has been coupled with “rapid uptake” in its new asthma indication, according to Sanofi.

More from news
Approximately 10 fully matching, plus 75 partially matching documents found.

Latest Intelligence

Innovation and digital health comms recognised at Communiqué Awards

The video played while the lift whisked its passengers into the congress, creating a six-minute video ‘experience’ which challenged dermatologists to change the way they treated atopic dermatitis. ... In order to target their message, the creative
Drug launches to watch in 2019

It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis,
Leo has its eyes on the prize

Psoriasis and dermatitis may seem the same in everybody but maybe the picture is more like it is in cancer where you have subsets. ... Bridging the gap. Leo is tracking increases in atopic dermatitis across Europe while psoriasis levels show no signs of
Pharma deals continue to slide

Phase II MAb to block IL-13 for treatment of atopic dermatitis.
Deal Watch September 2016

as well as other autoimmune disorders plus VTP-38543 for atopic dermatitis.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

Dr Desiree Luthman joins Verona Pharma

atopic dermatitis in the US.
Ziarco appoints Mike Grey to board of directors

Concerning his appointment, Grey said: “I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report

Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US.
Research Partnership has published a new patient Living with Atopic Dermatitis (US) report

Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. ... An attitudinal segmentation is included to help identify the unique groups of patients Atopic Dermatitis.
Atopic Dermatitis — Going Beyond the Pill

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
Research Partnership

Atopic Dermatitis — Going Beyond the Pill.